JO3509B1 - معدلات p2x7 - Google Patents

معدلات p2x7

Info

Publication number
JO3509B1
JO3509B1 JOP/2014/0096A JOP20140096A JO3509B1 JO 3509 B1 JO3509 B1 JO 3509B1 JO P20140096 A JOP20140096 A JO P20140096A JO 3509 B1 JO3509 B1 JO 3509B1
Authority
JO
Jordan
Prior art keywords
pyridinyl
phenyl
formula
pyradizinyl
thiophenyl
Prior art date
Application number
JOP/2014/0096A
Other languages
English (en)
Inventor
A Rudolph Dale
A Letavic Michael
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3509B1 publication Critical patent/JO3509B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يوجه هذا الاختراع بصفة عامة إلى مركب بالصيغة (I)، الصيغة (I) حيث: n هو عدد صحيح من 0-1؛ X يمثل الميثيلين إذا كان n يساوي 0، أو X يمثل الميثيلين أو الأكسيجين إذا كان n يساوي 1؛ R1 هو الفينيل أو البيريدينيل، حيث يستبدل الفينيل أو البيريدينيل اختياريًا بهالوجين أو ألكيل؛ و R2 هو الفينيل أو البيريدينيل أو البيرازينيل أو البيريميدينيل أو البيروليل أو البيرازوليل أو الثيازوليل أو الثيوفينيل، حيث يستبدل الفينيل أو البيريدينيل أو البيرازينيل أو البيريميدينيل أو البيروليل أو البيرازوليل أو الثيازوليل أو الثيوفينيل اختياريًا بهالوجين أو ألكيل أو هيدروكسي أو ألكوكسي. كما يتعلق الاختراع أيضاً بتركيبات دوائية تتألف من مركبات الصيغة (I). كما تقع أيضًا طرق تحضير مركبات الصيغة (I) واستخدامها ضمن نطاق الاختراع.
JOP/2014/0096A 2013-03-14 2014-03-12 معدلات p2x7 JO3509B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361785558P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
JO3509B1 true JO3509B1 (ar) 2020-07-05

Family

ID=50631041

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0096A JO3509B1 (ar) 2013-03-14 2014-03-12 معدلات p2x7

Country Status (9)

Country Link
US (3) US9102686B2 (ar)
EP (2) EP2970287B1 (ar)
JP (1) JP6294954B2 (ar)
AR (1) AR095421A1 (ar)
ES (2) ES2776654T3 (ar)
JO (1) JO3509B1 (ar)
TW (1) TWI627174B (ar)
UY (1) UY35447A (ar)
WO (1) WO2014152621A1 (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節物質
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
JO3509B1 (ar) * 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
WO2016039977A1 (en) * 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
JP6358639B2 (ja) 2015-04-24 2018-07-18 塩野義製薬株式会社 ６員複素環誘導体およびそれらを含有する医薬組成物
CA2997541C (en) * 2015-09-04 2022-01-11 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof
CN105596301A (zh) * 2016-01-29 2016-05-25 中国药科大学 一种以异喹啉为基本骨架的p2x7受体拮抗剂的纳米混悬剂及其制备方法
CN105503884B (zh) * 2016-02-17 2017-10-13 上海皓元生物医药科技有限公司 一种用于合成bet蛋白抑制剂的关键中间体的合成方法
EP3527568A4 (en) * 2016-10-17 2020-03-18 Shionogi & Co., Ltd BICYCLIC NITROGENATED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREFOR
JP7413368B2 (ja) 2018-09-28 2024-01-15 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ調節因子
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
CA3176946A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US905687A (en) 1908-07-14 1908-12-01 Samuel W Evans Jr Folding umbrella and cane.
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
US20060100233A1 (en) 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
DE602005022320D1 (de) 2004-08-23 2010-08-26 Merck Sharp & Dohme Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
EP1844003A4 (en) 2005-01-27 2010-09-22 Astrazeneca Ab NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
US8349858B2 (en) 2007-06-21 2013-01-08 Merck Sharp & Dohme Polycyclic guanine derivatives and use thereof
EP2185560A4 (en) 2007-08-10 2011-10-05 Lundbeck & Co As H HETEROARYLAMIDE ANALOGS
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
JP5369173B2 (ja) 2008-04-22 2013-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン若しくはイソキノリン置換ｐ２ｘ７アンタゴニスト
US8309578B2 (en) 2008-11-25 2012-11-13 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
WO2010125102A1 (en) * 2009-04-29 2010-11-04 Glaxo Group Limited 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
CA2793313C (en) 2010-04-02 2018-01-23 Euroscreen Sa Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
US20110252717A1 (en) 2010-04-16 2011-10-20 Graf Fernandez Rodrigo Foldable structures for a construction
US20130196986A1 (en) 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
CA2874621A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
BR112015008480A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
CA2895808A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
JO3516B1 (ar) 2013-03-06 2020-07-05 Janssen Pharmaceutica Nv مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
JP6603649B2 (ja) 2013-03-14 2019-11-06 キュラデブ ファーマ プライベート リミテッド キヌレニン経路の阻害剤
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
CA2902174A1 (en) 2013-03-14 2014-10-02 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
CN105189461B (zh) 2013-03-14 2018-05-15 葛兰素史克知识产权第二有限公司 2,3-二取代的1-酰基-4-氨基-1,2,3,4-四氢喹啉衍生物和它们作为溴结构域抑制剂的用途
JO3509B1 (ar) * 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節物質
ES2721018T3 (es) 2013-03-29 2019-07-26 Ogeda S A N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines

Also Published As

Publication number Publication date
US20140275056A1 (en) 2014-09-18
TW201522339A (zh) 2015-06-16
AR095421A1 (es) 2015-10-14
US9102686B2 (en) 2015-08-11
EP3309161B1 (en) 2019-12-18
US9540388B2 (en) 2017-01-10
JP6294954B2 (ja) 2018-03-14
HK1254111A1 (en) 2019-07-12
HK1218649A1 (en) 2017-03-03
WO2014152621A1 (en) 2014-09-25
US20170088550A1 (en) 2017-03-30
EP2970287A1 (en) 2016-01-20
EP2970287B1 (en) 2017-11-01
JP2016513702A (ja) 2016-05-16
US10053462B2 (en) 2018-08-21
TWI627174B (zh) 2018-06-21
UY35447A (es) 2014-09-30
ES2652648T3 (es) 2018-02-05
EP3309161A1 (en) 2018-04-18
US20160039836A1 (en) 2016-02-11
ES2776654T3 (es) 2020-07-31

Similar Documents

Publication Publication Date Title
SA515361086B1 (ar) Fasn مركبات وتركيبات جديدة لتثبيط
AR095421A1 (es) Moduladores de p2x7
EP4272824A3 (en) Substituted 2-azabicycles and their use as orexin receptor modulators
UA118549C2 (uk) 2,3-дизаміщені похідні 1-ацил-4-аміно-1,2,3,4-тетрагідрохіноліну та їх застосування як інгібіторів бромодомену
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
MX347459B (es) Nuevos compuestos y composiciones para la inhibición de nampt.
PH12015502030A1 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
IN2014CN01024A (ar)
MY169267A (en) New aryl-quinoline derivatives
MY161134A (en) Piperazine compound having a pgds inhibitory effect
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
PH12015500654A1 (en) Pest controlling composition and use thereof
PL401473A1 (pl) Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania
MX2015016400A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
MX2016007985A (es) Compuestos de fluorofenilpirazol.
MX2015015058A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
SA519400868B1 (ar) معدلات عطرية غير متجانسة لأشعة جاما لمستقبل يتيم ذي علاقة بريتينويد
CO6660459A2 (es) Derivados de 4-(metilaminofenoxi)piridin-3-il-benzamina para tratar cancer
IN2015DN02514A (ar)
LV14984A (lv) 2-Fenilamino-4-(piridīn-3-il)-6-perfluoralkilpirimidīni
IN2013MU01256A (ar)
GB201013509D0 (en) Compounds
NZ751449A (en) Novel compounds and compositions for inhibition of fasn
UA70747U (ru) Тиосемикарбазоны 1,2-дизамещенных 4-хлороимидазол-5-карбальдегидов, проявляющие противотуберкулезную активность